NVS - Another Arthritis Blockbuster Drug Faces Generic Competition: Novartis' Sandoz Inks Pact With Samsung Bioepis | Benzinga
Sandoz, a generic and biosimilar medicines unit of Novartis AG (NYSE: NVS), has entered a development and commercialization agreement with Samsung Bioepis.
The agreement provides Sandoz exclusive rights to commercialize the biosimilar SB17 ustekinumab in the US, Canada, EEA, Switzerland, and the U.K. Other specific terms of the agreement are confidential.
"It will further strengthen our immunology patient offering and means we now have five potential high-value upcoming biosimilar launches over the next few years," ...